Metastatic and triple-negative breast cancer: challenges and treatment options.
Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. · 2018
Read Metastatic and triple-negative breast cancer: challenges and treatment options. by Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6133085.txt.
Description
Al-Mahmood and co-authors wrote a review in Drug Delivery and Translational Research on metastatic and triple-negative breast cancer. Triple-negative tumors lack three receptors that many drugs target. That leaves fewer treatment options. They make up about 10 to 20 percent of breast cancers. Spread to distant organs is the main danger.
The review covers standard care, from surgery and radiation to chemo and hormone drugs. It then turns to newer tactics. Targeted drugs, gene therapy, and immune therapy all feature. One nano-based plan pairs gene silencing with gefitinib against the EGFR pathway. The authors stress that combined treatments are usually needed.
Catalog record
| CREATOR | Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 132 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |